Compare Stocks → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CGTXNASDAQ:TCRRNASDAQ:UPTD Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$1.91-4.5%$1.93$0.90▼$3.49$76.48M1.54181,369 shs88,024 shsTCRRTCR2 Therapeutics$1.48-5.7%$1.65$0.82▼$3.88$58.11M1.95494,777 shs3.91 million shsUPTDTradeUP Acquisition$1.07-0.9%$1.51$6.88▼$33.00$2.32M0.12270,115 shs526 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics-4.50%-3.54%-5.91%-15.86%+21.66%TCRRTCR2 Therapeutics0.00%0.00%0.00%0.00%-25.25%UPTDTradeUP Acquisition+4.85%+2.66%-1.82%-6.10%-89.98%He Is Giving Away Bitcoin (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGTXCognition Therapeutics2.3701 of 5 stars3.53.00.00.01.04.20.0TCRRTCR2 TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AUPTDTradeUP AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGTXCognition Therapeutics3.00Buy$6.67249.04% UpsideTCRRTCR2 TherapeuticsN/AN/AN/AN/AUPTDTradeUP AcquisitionN/AN/AN/AN/ACurrent Analyst RatingsLatest TCRR, CGTX, and UPTD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024CGTXCognition TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/27/2024CGTXCognition TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.00(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGTXCognition TherapeuticsN/AN/AN/AN/A$0.76 per shareN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/A$2.58 per shareN/AUPTDTradeUP AcquisitionN/AN/AN/AN/A($1.59) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGTXCognition Therapeutics-$25.79M-$0.86N/AN/AN/AN/A-83.48%-63.07%8/13/2024 (Estimated)TCRRTCR2 Therapeutics-$151.82M-$4.20N/AN/AN/AN/A-97.81%-69.35%N/AUPTDTradeUP Acquisition-$1MN/A0.00∞N/AN/AN/A-3.38%N/ALatest TCRR, CGTX, and UPTD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023CGTXCognition Therapeutics-$0.38-$0.27+$0.11-$0.27N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGTXCognition TherapeuticsN/AN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/AN/AUPTDTradeUP AcquisitionN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGTXCognition TherapeuticsN/A3.373.37TCRRTCR2 TherapeuticsN/A2.962.96UPTDTradeUP AcquisitionN/A0.090.09OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGTXCognition Therapeutics43.35%TCRRTCR2 Therapeutics64.76%UPTDTradeUP Acquisition34.95%Insider OwnershipCompanyInsider OwnershipCGTXCognition Therapeutics23.80%TCRRTCR2 Therapeutics25.01%UPTDTradeUP Acquisition55.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCGTXCognition Therapeutics2540.04 million30.51 millionNot OptionableTCRRTCR2 Therapeutics13739.26 million29.44 millionNot OptionableUPTDTradeUP Acquisition2,0212.17 million973,000Not OptionableTCRR, CGTX, and UPTD HeadlinesSourceHeadlineEstrella Immunopharma stock plunges in market debut after SPAC mergermsn.com - October 2 at 11:52 PMSPAC TradeUp, Estrella Biopharma complete merger; shares to debut Oct. 2msn.com - September 29 at 3:26 PMTradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combinationfinance.yahoo.com - September 29 at 3:26 PMTradeUP (UPTD) Stock is Up: What's Going On?benzinga.com - September 21 at 8:30 PMTradeUp (NASDAQ: UPTD) up 67% - Hey, maybe a deal really will be done heredhakatribune.com - September 15 at 4:38 PMWhy TradeUP Acquisition (UPTD) Stock Is Rocketing Higherbenzinga.com - September 1 at 3:19 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCognition TherapeuticsNASDAQ:CGTXCognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.TCR2 TherapeuticsNASDAQ:TCRRTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.TradeUP AcquisitionNASDAQ:UPTDTradeUP Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
